Pharmaceuticals & Therapeutics

Processa Pharmaceuticals completes enrollment for a pivotal analysis of its NGC-Cap therapy, offering new hope for a safer, more effective cancer treatment.

BridGene Biosciences adds Nobel winner Dr. Bruce Beutler to its board, gaining immense credibility for its mission to create drugs for intractable diseases.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

With a $257M war chest and a veteran team, BlossomHill will showcase its innovative pipeline for lung cancer and leukemia at the pivotal JPM conference.

With surging revenue for its cholesterol drugs and new guideline backing, Esperion outlines its strategy for profitability and pipeline expansion.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

South Korea's Curogen secures major national funding and targets global partners at the JP Morgan conference, advancing novel therapies for IBD and HS.

A global RFA leader unveils a new identity, reflecting a strategic shift from pure engineering to a focus on the patient's quality of life.

Tango Therapeutics adds seasoned CFO Sung Lee to its board, a strategic move to guide its lead cancer drug, vopimetostat, through late-stage trials.

Sanofi is investing up to $2.56 billion in Earendil Labs' AI platform to discover next-gen bispecific antibodies for complex autoimmune diseases.

Health Canada has approved JERAYGO, the first new hypertension drug class in 30 years, offering a lifeline to patients with hard-to-treat high blood pressure.

The eye health giant has refinanced a massive $2.8B in loans, extending debt maturity and cutting interest costs to bolster its long-term strategy.

All eyes are on GH Research ahead of a crucial Jan. 5 announcement on the FDA status of its fast-acting drug for treatment-resistant depression.

A major new partnership is funding research to develop vital diagnostic tests for FTD, aiming to end years-long diagnostic delays for families.

Lantheus sells its legacy SPECT business to fusion-tech firm SHINE, sharpening its focus on high-growth PET diagnostics and next-gen cancer therapies.

With a blockbuster 2025 in the books, Boston Scientific's leadership faces intense scrutiny at upcoming investor events to prove its growth is sustainable.

Samsung Bioepis is now directly selling its Lucentis biosimilar in Europe, a move set to increase competition and improve access to vital eye disease treatments.

Neovii Pharmaceuticals names Frédéric Prince its next CEO, bringing deep oncology and gene therapy experience from Roche to steer its next growth phase.

South Korea's KLMBio is accelerating its global push with major investments in production and new products to capture the booming regenerative medicine market.

World No.1 table tennis star Sun Yingsha joins La Roche-Posay in a strategic play for Gen-Z hearts and the massive Asian beauty market.